Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)

被引:23
|
作者
Xu, Yanyan [1 ,2 ]
Egido, Estefania [1 ,3 ,4 ]
Li-Blatter, Xiaochun [1 ]
Mueller, Rita [1 ]
Merino, Gracia [3 ,4 ]
Berneche, Simon [1 ,2 ]
Seelig, Anna [1 ]
机构
[1] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland
[2] Swiss Inst Bioinformat, CH-4056 Basel, Switzerland
[3] Univ Leon, INDEGSAL, E-24071 Leon, Spain
[4] Univ Leon, Fac Vet, Dept Biomed Sci Physiol, E-24071 Leon, Spain
基金
瑞士国家科学基金会;
关键词
BRAIN-BARRIER PERMEATION; MULTIDRUG-RESISTANCE; ATPASE ACTIVITY; DRUG TRANSPORT; SUBSTRATE RECOGNITION; STRUCTURAL BASIS; PLASMA-MEMBRANE; LIVING CELLS; SITES; ACTIVATION;
D O I
10.1021/acs.biochem.5b00649
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ATP binding cassette (ABC) transporters ABCG2 and ABCB1 perform ATP hydrolysis-dependent efflux of structurally highly diverse compounds, collectively called allocrites. Whereas much is known about allocrite-ABCB1 interactions, the chemical nature and strength of ABCG2-allocrite interactions have not yet been assessed. We quantified and characterized interactions of allocrite with ABCG2 and ABCB1 using a set of 39 diverse compounds. We also investigated potential allocrite binding sites based on available transporter structures and structural models. We demonstrate that ABCG2 binds its allocrites from the lipid membrane, despite their hydrophilicity. Hence, binding of allocrite to both transporters is a two-step process, starting with a lipid water partitioning step, driven mainly by hydrophobic interactions, followed by a transporter binding step in the lipid membrane. We show that binding of allocrite to both transporters increases with the number of hydrogen bond acceptors in allocrites. Scrutinizing the transporter translocation pathways revealed ample hydrogen bond donors for allocrite binding. Importantly, the hydrogen bond donor strength is, on average, higher in ABCG2 than in ABCB1, which explains the higher measured affinity of allocrite for ABCG2. pi-pi stacking and pi-cation interactions play additional roles in binding of allocrite to ABCG2 and ABCB1. With this analysis, we demonstrate that these membrane-mediated weak electrostatic interactions between transporters and allocrites allow for transporter promiscuity toward allocrites. The different sensitivities of the transporters to allocrites' charge and amphiphilicity provide transporter specificity. In addition, we show that the different hydrogen bond donor strengths in the two transporters allow for affinity tuning.
引用
收藏
页码:6195 / 6206
页数:12
相关论文
共 50 条
  • [1] Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)
    Hofman, Jakub
    Kucera, Radim
    Cihalova, Daniela
    Klimes, Jiri
    Ceckova, Martina
    Staud, Frantisek
    PLOS ONE, 2013, 8 (10):
  • [2] Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice
    Wang, Jing
    Bruin, Maaike A. C.
    Gan, Changpei
    Lebre, Maria C.
    Rosing, Hilde
    Beijnen, Jos H.
    Schinkel, Alfred H.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 581
  • [3] Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)
    Tournier, Nicolas
    Chevillard, Lucie
    Megarbane, Bruno
    Pirnay, Stephane
    Scherrmann, Jean-Michel
    Decleves, Xavier
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (07): : 905 - 915
  • [4] Predicting Activators and Inhibitors of the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1) Based on Mechanistic Considerations
    Egido, Estefania
    Mueller, Rita
    Li-Blatter, Xiaochun
    Merino, Gracia
    Seelig, Anna
    MOLECULAR PHARMACEUTICS, 2015, 12 (11) : 4026 - 4037
  • [5] Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar
    Kuehnle, Matthias
    Egger, Michael
    Mueller, Christine
    Mahringer, Anne
    Bernhardt, Guenther
    Fricker, Gert
    Koenig, Burkhard
    Buschauer, Armin
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (04) : 1190 - 1197
  • [6] Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux
    Agarwal, Sagar
    Sane, Ramola
    Gallardo, Jose L.
    Ohlfest, John R.
    Elmquist, William F.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (01): : 147 - 155
  • [7] Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening
    Tournier, Nicolas
    Valette, Heric
    Peyronneau, Marie-Anne
    Saba, Wadad
    Goutal, Sebastien
    Kuhnast, Bertrand
    Dolle, Frederic
    Scherrmann, Jean-Michel
    Cisternino, Salvatore
    Bottlaender, Michel
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (03) : 415 - 423
  • [8] Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2)
    Ieiri, Ichiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (01) : 85 - 105
  • [9] Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
    Lagas, Jurjen S.
    van Waterschoot, Robert A. B.
    van Tilburg, Vicky A. C. J.
    Hillebrand, Michel J.
    Lankheet, Nienke
    Rosing, Hilde
    Beijnen, Jos H.
    Schinkel, Alfred H.
    CLINICAL CANCER RESEARCH, 2009, 15 (07) : 2344 - 2351
  • [10] Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics
    Poller, Birk
    Iusuf, Dilek
    Sparidans, Rolf W.
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (05) : 729 - 735